Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Ten patients with previously untreated stage III/IV low grade histology non-Hodgkin's lymphoma received a 1-hour intravenous infusion of Didemnin B 2.3 mg/m2 weekly for 4 weeks repeated every 6 weeks. 40% of patients experienced significant hypersensitivity reactions, one of which was life-threatening, despite premedication with diphenhydramine and cimetidine. Other toxicities included nausea, vomiting, fatigue, diarrhea and skin rashes. No objective responses were seen. Given the serious toxicity and lack of activity in a non-pretreated group of patients, the study was closed early. Further investigation of Didemnin B at this dose and schedule is not recommended.
Goss
G
G
Ottawa General Hospital, Canada.
Muldal
A
A
Lohmann
R
R
Taylor
M
M
Lopez
P
P
Armitage
G
G
Steward
W P
WP
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D047630:Depsipeptides; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D047630:Depsipeptides; D010456:Peptides, Cyclic; C030051:didemnins